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Background: The number of primary care referrals of women with breast symptoms to symptomatic breast units
(SBUs) has increased exponentially in the past decade in Ireland. The aim of this study is to develop and validate a
clinical prediction rule (CPR) to identify women with breast cancer so that a more evidence based approach to
referral from primary care to these SBUs can be developed.
Methods: We analysed routine data from a prospective cohort of consecutive women reviewed at a SBU with
breast symptoms. The dataset was split into a derivation and validation cohort. Regression analysis was used to
derive a CPR from the patient’s history and clinical findings. Validation of the CPR consisted of estimating the
number of breast cancers predicted to occur compared with the actual number of observed breast cancers across
deciles of risk.
Results: A total of 6,590 patients were included in the derivation study and 4.9% were diagnosed with breast cancer.
Independent clinical predictors for breast cancer were: increasing age by year (adjusted odds ratio 1.08, 95% CI 1.07-1.09);
presence of a lump (5.63, 95% CI 4.2-7.56); nipple change (2.77, 95% CI 1.68-4.58) and nipple discharge (2.09, 95% CI 1.
1-3.97). Validation of the rule (n = 911) demonstrated that the probability of breast cancer was higher with an increasing
number of these independent variables. The Hosmer-Lemeshow goodness of fit showed no overall significant difference
between the expected and the observed numbers of breast cancer (χ2HL: 6.74, p-value: 0.56).
Conclusions: This study derived and validated a CPR for breast cancer in women attending an Irish national SBU. We
found that increasing age, presence of a lump, nipple discharge and nipple change are all associated with increased risk
of breast cancer. Further validation of the rule is necessary as well as an assessment of its impact on referral practice.
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In 2007, there were 2,463 new cases of breast cancer
diagnosed in Ireland making it the most common inva-
sive cancer in Irish women [1]. Advances in diagnosis
and treatment have resulted in an increase in survival
rates from breast cancer [2,3]. In spite of this, breast
cancer remains the biggest cause of death from cancer
in women in Ireland [1]. Following centralisation of
breast cancer services, the National Cancer Control* Correspondence: rosegalvin@rcsi.ie
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unless otherwise stated.Programme (NCCP) introduced clinical guidelines to en-
hance the referral process to symptomatic breast units
(SBU) [4]. Based on these guidelines, General Practi-
tioners (GPs) act as gatekeepers responsible for clinical
assessment and are required to prioritise patient referral
as ‘urgent’ , ‘early’ or ‘routine’ for subsequent examination
at a SBU within two weeks, six weeks or 12 weeks respect-
ively [4]. Figures from the 2012 NCCP report showed a
60% increase in SBU attendees from 23,575 in 2006 to
37,631 in 2010 [5]. The proportional increase in the
benign: malignant ratio of patients in SBU means that a
review of the diagnostic criteria, and their underlying evi-
dence base is needed.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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quantify the independent impact of factors from a patients
history, physical examination and diagnostic tests and
stratify patients according to the probability of having a
target disorder [6]. Before widespread clinical implemen-
tation, CPRs should undergo three stages of development:
(i) Derivation: factors with predictive power are identified
to develop the CPR; (ii) Validation: The CPR is tested in a
new population for reliability and accuracy; and (iii) Im-
pact analysis: The impact of the rule may be examined in
terms of physician behavior, patient outcomes, or costs
[7]. CPRs offer one way of implementing evidence based
medicine, especially if incorporated into clinical decision
support systems, at the point of patient care. A CPR re-
cently derived by McCowan et al. [8] aimed to stratify pa-
tients at risk of breast cancer. Independent clinical
predictors for breast cancer were increasing age by year,
presence of a discrete lump, breast thickening, lymph-
adenopathy and lump ≥2 cm. Patients with a score of ≥4
had a 5-8% probability of having breast cancer and the
authors recommended that patients in this group should
be referred for further evaluation in a SBU [8]. However
in Ireland, two of the five variables included in the CPR by
McCowan et al. [8] are not routinely coded in the SBU
database including lump size (<2 cm/≥2 cm) and breast
thickening so the existing CPR cannot be validated. The
aim of this study is to develop and validate a CPR for diag-
nosis of breast cancer using routine data collated in an Irish
national SBU so that a more evidence based approach to
referral from the primary care setting can be developed.
Methods
Study design and setting
We analysed routine data collected from a prospective
cohort of consecutive patients reviewed at the SBU in
Beaumont hospital with breast symptoms. Beaumont hos-
pital has one of eight designated SBUs in Ireland. The
SBU serves north county Dublin and the north Leinster
region with a mix of urban and rural patients. Six breast
surgeons run eight triple assessment clinics each week
and there are four clinics dedicated to return patients and
non-urgent new referrals. The SBU database (Dendrite
Clinical Systems Ltd, Oxford, UK) at Beaumont contains
information on clinical, radiological and pathological data
for patients attending the SBU. Ethical approval was re-
ceived from the Research Ethics Committee (REC) at the
Royal College of Surgeons in Ireland and from Beaumont
Hospital REC. The STROBE standardised reporting guide-
lines for cohort studies were followed to ensure standar-
dised conduct and reporting of the study [9].
Study population
This study comprised two cohorts of patients, a derivation
cohort and a validation cohort. The first stage related tothe use of data contained in the SBU from March 2011-
June 2012 (inclusive) to formulate or derive a new breast
cancer CPR (derivation cohort). In the second stage of the
study, we validated the rule in patients entered into
the database from July 2012-December 2012. Exclusion
criteria were: male gender, return patients or those with
known breast cancer. All data was anonymised using
standardised operating procedures by a data analyst at
Beaumont hospital to protect patient confidentiality and
privacy. The anonymised dataset was then transferred to
the research team for analysis.Predictor variables
Patients referred to the SBU in Beaumont Hospital un
dergo triple assessment. This is a three step process con-
sisting of clinical examination, radiological examination
and histological examination. The first stage comprises
identifying the reason for referral/clinical history and a
clinical examination of the breasts and axillae by a breast
surgeon. For the purposes of our study and in-keeping
with our overall aim to identify a more evidence based re-
ferral process from the primary care setting, we used the
variables recorded at the time of presentation to the GP as
a proxy for the findings on clinical examination. Variables
recorded are binary and include the presence/absence of:
mastalgia, lump, abscess, inflammation, skin change, ul-
ceration, nipple discharge, nipple changes, family history
and nodularity. A free-text box includes an option to rec-
ord additional symptoms. Patients may then be referred
for a radiological examination of the breast and axillae.
However, if no abnormality is detected on clinical examin-
ation in a patient <35 years no imaging is requested. If no
abnormality is identified in a patient ≥35 years, a baseline
bilateral mammogram is ordered which will act as a refer-
ence for all future breast imaging. In patients presenting
with an abnormality on clinical examination (for example
a lump), she is then referred for a bilateral mammogram
and an ultrasound scan of the breast containing the ab-
normality. In cases where an abnormality is visible on
mammogram and ultrasound, a core biopsy is carried out
by the consultant radiologist. This process involves infil-
tration of the skin and breast tissue with local anaesthetic
followed by ultrasound guided biopsy of the abnormality.
Three to five biopsy specimens are obtained and fixed in
formalin before transfer to the pathology laboratory. All bi-
opsy specimens are examined macroscopically and micro-
scopically by a consultant pathologist.Outcome
The outcome of breast cancer is recorded as a binary
variable and is based on the findings from diagnostic
histology on biopsy or excision biopsy.
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Derivation study
Descriptive statistics including means and standard devia-
tions were computed. The first stage of the analysis was to
investigate the univariate associations for the explanatory
variables - clinical history and examination findings with
the outcome of breast cancer. These results are expressed
as odd ratios (ORs) where values >1 indicate increased
odds of the presence of breast cancer and values of <1
suggest decreased odds of breast cancer. For inclusion
into the multivariable logistic regression model, explana-
tory variables had to be considered of prior clinical im-
portance or have a threshold p-value of ≤ 0.15 in the
univariate analysis [8].
The final multivariate regression model was used to cre-
ate a clinical prediction rule. We followed the method
used by the Framingham Heart Study to calculate points
associated with each level/category of our risk factors [10].
This points system was developed to make complex statis-
tical models useful to practitioners by simplifying the esti-
mation of risk. Firstly the estimates of the regression
coefficients (equivalent to the logORs) of the multivariable
logistic regression model were found and the referent risk
factor profile determined. Secondly we calculated how far
all other risk levels/categories were from the referent
level/category (in regression units) and used this to assign
integer points to each level/category of each risk factor.
Hence, a specific risk factor profile could be obtained by
summing these integer points. Finally, a reference table,
with risk estimates for each points total was constructed.
Validation study
We examined two aspects of validity of our results, cali-
bration and discrimination. Calibration (or reliability)
reflects how closely predicted outcomes agree with the
actual outcomes. The model was calibrated by applying
the regression coefficients from the derivation cohort to
the individuals in the validation cohort and generating
expected probabilities of breast cancer. Deciles of risk cat-
egories of expected and observed breast cancer cases were
generated for comparison using the Hosmer-Lemeshow
test (HLT) [11].
Discrimination refers to the ability of the rule to distin-
guish correctly the patients with different outcomes
(breast cancer/no breast cancer). The c statistic, or area
under the curve (AUC), with 95% confidence interval (CI)
was estimated to describe model discrimination. The area
under a ROC curve quantifies the overall ability of the test
to discriminate between those individuals with breast can-
cer and those without breast cancer. The c statistic ranges
from 0.5 (no discrimination) to a theoretical maximum of
1, values between 0.7 and 0.9 represent moderate accuracy
and greater than 0.9 represents high accuracy [12]. A c
statistic of 1 represents perfect discrimination, wherebyscores for all cases with breast cancer are higher than
those for all the non-cases with no overlap. All statistical
analyses were completed using STATA (version 12, Stata
Corp, College Station, Texas, USA).
Results
Overall descriptive characteristics
There were 7,784 unique patient consultations recorded
at the SBU in Beaumont hospital during the study period.
A total of 7,567 patients (97.2%) were female and 217
(2.8%) were male. All male patients were excluded from
our analysis. A further 66 patients were also excluded due
to age <18 years (n = 62) and diagnosis of recurrent or
metastatic breast cancer (n = 4), leaving 7,501 for analysis
(6,590 in the derivation study and 911 in the validation
study). The mean age of these women was 44 years (SD
13.6 years, range 18–97 years). A total of 1,582 women
underwent a biopsy in the entire cohort and 357 of these
patients (4.8%) were diagnosed with breast cancer, with
the remainder (n = 7144, 95.2%) having either benign
breast disease or normal breasts. Table 1 displays the fre-
quency of symptom presentation in the cohort (n = 7,501).
Almost half of patients (n = 3,735) presented with a breast
lump and one third presented with mastalgia (n = 2,488).
Derivation study
The derivation study examined patients attending the
Beaumont hospital SBU between March 2011 and June
2012 (inclusive). A total of 6,590 patients were evaluated
in this initial stage of the study. The mean age of these
women was 44.3 years (SD 13.6 years, range 18–97
years) and the most common reason for referral to the
SBU was the presence of a lump (n = 3,244). A primary
breast cancer diagnosis was made in 320 patients (4.9%)
and the remainder (n = 6,270, 95.1%) were diagnosed
with no abnormality or benign breast pathology only. In
the derivation cohort, 86.9% of the patients who were diag-
nosed with breast cancer were triaged as urgent (n = 278).
Almost all referrals were received from a general practi-
tioner (n = 6,524, 99%), representing 95% of the subsequent
cancer diagnoses. Other sources of referral included refer-
rals from the accident and emergency department (n = 17),
hospital inpatient referrals (n = 25) or referrals from other
hospitals (n = 24).
Univariate associations for clinical features of women
presenting with breast symptoms are displayed in Table 2.
Our results show that increasing age, presence of a lump
and nipple changes were all associated with breast cancer.
The results of the multivariate derivation model are
expressed as odds ratios and displayed in Table 3. We also
included nipple discharge in the final multivariate logistic
regression model as it may have been recorded as a proxy
for pathologic nipple discharge, a variable associated with
an increased incidence of breast cancer [13]. The regression
Table 1 Summary of presenting symptoms
Symptom* Frequency of symptom in entire
population (n = 7,501)
Frequency of symptom in those
with breast cancer (n = 357)
Frequency of symptom in those
without breast cancer (n = 7,144)
Abscess 2.3% (n = 173) 1.1% (n = 4) 2.3% (n = 169)
Discomfort 0.8% (n = 61) 0% (n = 0) 0.9% (n = 61)
Inflammation 2.3% (n = 173) 1.1% (n = 4) 2.3% (n = 169)
Family history** 33.0% (n = 2,487) 29.0% (n = 104) 39.8% (n = 2,383)
Lump 49.8% (n = 3,735) 74.8% (n = 267) 48.5% (n = 3,468)
Nipple changes 4.1% (n = 306) 7.8% (n = 28) 3.9% (n = 278)
Skin changes 1.1% (n = 84) 2.5% (n = 9) 1.0% (n = 75)
Nipple discharge 3.5% (n = 263) 4.2% (n = 15) 3.5% (n = 248)
Ulceration 1.1% (n = 84) 2.5% (n = 9) 1.0% (n = 75)
Nodularity 0.2% (n = 14) 0.3% (n = 1) 0.2% (n = 13)
Mastalgia 33.2% (n = 2,488) 10.4% (n = 37) 34.3% (n = 2,451)
*Patients may present with more than one symptom.
**Unknown/not stated (n = 1,221).
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Table 3 [10].Validation study
The validation study comprised patients attending the
Beaumont hospital SBU between July-December 2012
(inclusive). A total of 911 patients were included in the
validation study. The mean age of these women was
41.5 years (SD 13.3 years, range 18–89 years). Thirty seven
patients in this group were diagnosed with breast cancer
following triple assessment (4.06%) with the remainder
(n = 874, 95.9%) having either normal breasts or benign
breast disease. The majority of patients (n = 22, 89.2%)
who were diagnosed with breast cancer were triaged as ur-
gent. The most common reason for referral to the SBU
was a discrete breast lump which was present in 53.9% of
referrals (n = 491).Table 2 Univariate associations between explanatory variable
Explanatory variable Unadjusted odds ratio
Age 1.07
Abscess 0.53
Inflammation 0.53
Family history 0.99
Lump 3.33
Nipple changes 1.93
Skin changes 1.73
Nipple discharge 1.19
Ulceration 1.73
Nodularity 2.18
Note: Explanatory variables had to be considered of prior clinical importance (nipp
threshold p-value of ≤ 0.15.Calibration
Based on the derivation model, the probability for having
breast cancer in the validation cohort was used to divide
subjects into deciles. In each of the deciles, the number of
expected breast cancer cases (expected) was compared to
the actual number of breast cancer cases (observed).
Figure 1 shows that the expected number of breast cancer
cases was less than the observed number of cases for some
deciles of risk. This is particularly evident for patients at
highest risk of breast cancer. For example the expected
number of people with breast cancer was less than the
number observed for the 9th and 10th deciles of risk. Even
though Figure 1 indicates that the number of people with
breast cancer was slightly underestimated for those high-
est at risk, the Hosmer-Lemeshow goodness of fit showed
no significant difference between the expected and the
observed numbers of breast cancer (χ2HL: 6.74, p-value:
0.56).s and breast cancer in the derivation cohort
95% confidence interval (CI) P-value
1.07-1.08 <0.01
0.20-1.44 0.22
0.20-1.44 0.22
0.91-1.07 0.71
2.56-4.30 <0.01
1.24-3.01 <0.01
0.69-4.35 0.24
0.67-2.11 0.55
0.69-4.35 0.24
0.28-17.26 0.46
le discharge may indicate pathologic nipple discharge) or be associated with a
Table 3 Adjusted odds ratios and regression coefficient for the presence of breast cancer from the derivation model
Explanatory variable Adjusted OR (95% CI) Regression coefficient P-value
Increasing age (additional year) 1.08 (1.07-1.09) 0.08 <0.01
Presence of a lump 5.63 (4.20-7.56) 1.73 <0.01
Nipple change 2.77 (1.68-4.58) 1.02 <0.01
Nipple discharge 2.09 (1.10-3.97) 0.74 0.03
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Figure 2 shows the receiver operating curve (ROC), a graph
of the sensitivity (y‐axis) and the specificity (x-axis). In this
case the area under the curve is 0. 86 (95% CI 0.79 - 0.92),
indicating moderate accuracy of the CPR.
The simplified scoring system based on the regression
model is displayed in Table 4. The variables included from
the regression model were age, lump, nipple change and
nipple discharge. Age was divided up into 6 categories:
18–29, 30–39, 40–49, 50–59, 60–69 and 70–99 years.
Table 5 displays the incremental value of the compo-
nents of the CPR and the calculation of different
thresholds of risk. For example, a total score of 4
points is attributed to almost a 2% risk of breast can-
cer, 6 points has nearly a 6% risk, a score of ≥8 carries
17% risk and a score ≥11 has more than a 50% risk of
breast cancer.Discussion
Statement of principal findings
This study derived and validated a clinical prediction rule
for diagnosis of breast cancer in symptomatic women
attending an Irish national symptomatic breast unit over a
22 month period. The incidence of breast cancer was 4.9%
in the overall cohort. Our results also show that increasing
age, presence of a lump, nipple discharge and nipple
change were all associated with breast cancer. Validation
of the rule indicates that the probability of breast cancer is
higher with an increasing number of these independent
variables.Figure 1 The expected and observed breast cancers by decile of predResults in the context of the current literature
Almost five percent of referred patients in our study were
found to have breast cancer, a figure similar to the Irish in-
cidence of female breast cancer that was reported at 5.6%
in 2011 [5]. The benign:malignant ratio in our study (1:19)
is higher than that reported in a similar UK study where
the ratio of benign to malignant detections was 1:13 in
women referred to a symptomatic breast clinic [8]. The
higher ratio in our study is probably a reflection of an in-
creasing number of referrals of patients with benign breast
disease to the SBU with a resultant reduction in the overall
rate of cancer detection. US based studies tend to have
lower ratios, most likely due to differing referral pathways
and access patterns between health care systems [8,14].
The literature to date is limited around methods to
identify women at risk of breast cancer, particularly in
terms of identifying and prioritising those at greatest risk.
A UK study by Campbell et al. [15] prospectively gathered
data on 2064 patients referred to a breast unit over a
12 month period. The authors reported that increasing
age (OR = 1.08, 95% CI 1.07-1.09, p < 0.001) and the pres-
ence of a discrete lump (OR = 5.08, 95% CI 3.07-8.4,
p < 0.001) were significant discriminatory predictors of
breast cancer, in keeping with the findings of our study.
The presence of pain was not associated with the presence
of breast cancer, similar to our study. A later study by
McCowan et al. [8] also reported that increasing age, pres-
ence of a discrete lump, presence of a lump tethered to
the skin or chest wall, a lump ≥2.0 cm in size, presence of
breast thickening, lymphadenopathy all independently in-
creased the probability of a woman having breast cancer.icted risk in the validation cohort.
Figure 2 Receiver operating curve for validation cohort.
Table 5 Risks associated with the total scores for onward
referral of breast cancer*
Total score Estimate of risk
0 0.0016
1 0.0030
2 0.0054
3 0.0099
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factors from a patient’s history and clinical examination
and subsequently stratifies patients according to their
probability of having a breast cancer. The clinical vari-
ables included in the clinical prediction rule have clinical
and content validity. The presence of a breast lump is
the most common presenting and predictive symptom in
women with breast cancer [8,16,17] while the incidence of
breast cancer is consistently shown to be associated with
increasing age [8,16,18]. Pathologic nipple discharge has
also been associated with an increased incidence of breast
cancer [13,19,20]. We included the variable ‘nipple dis-
charge’ in our final model as it may have been recorded as
a proxy for pathologic discharge. Almost one third of the
women in our cohort presented with mastalgia, a figure
higher than that reported two previous studies of this
nature [8,16] but mastalgia has been reported to affectTable 4 Scoring System for onward referral for
breast cancer
Risk factor Scoring
Lump 3
Age 18-29 0
Age 30-39 1
Age 40-49 3
Age 50-59 4
Age 60-69 5
Age 70-99 8
Nipple change 2
Nipple discharge 1between 10-30% of women [21]. We found that the pres-
ence of mastalgia was not independently predictive of
breast cancer, similar to the findings of McCowan and col-
leagues [8]. Research also indicates that women with a
family history of breast cancer are more likely to overesti-
mate their risk of breast cancer than women without this
risk factor [22,23]. Furthermore, GPs are also more likely
to refer women with a history of breast cancer [24]. We
found that family history, present in one third of the entire
cohort, was not predictive of breast cancer. This finding is
at odds with other studies [16,25] and may be due to the
different methods of data collection resulting in different
prevalence estimates or the differences in settings of care.
Other variables not recorded in our database that have
been found to be independently predictive of a diagnosis of
breast cancer include breast thickening, lymphadenopathy,
size of lump, alcohol use, post-menopausal bleeding, in-
creasing affluence, and venous thrombo-embolism [8,16].
Previous studies have questioned the value of the two
week referral policy due to the low number of cancers de-
tected in this group and have also discussed the validity of
what is in essence a two tier system, whereby women
triaged as ‘non-urgent’ referrals have to wait longer to see
a specialist [26,27]. Our study supports the clinical utility
of this referral process as we found that 87% the women
who were subsequently diagnosed with breast cancer were
triaged as ‘urgent’, indicating that the waiting time be-
tween assessment by the GP and subsequent appointment
in the SBU was less than two weeks.4 0.0178
5 0.0320
6 0.0568
7 0.0989
8 0.1667
9 0.2671
10 0.3991
11 0.5475
12 0.6880
13 0.8007
14 0.8798
*Referral process guided by total score. The risk of breast cancer is almost 2%
once a woman scores 4 points and over 5% once the score reaches a
threshold of ≥6 on the CPR.
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This pragmatic study examined routinely collected data
from over 7,500 women with suspected breast cancer to
determine the factors that were most predictive of breast
cancer. The predictor variables identified are easily
recorded in the clinical setting and there were very few
patients excluded from the analysis, optimising the exter-
nal validity of the study. The incidence of cancer in our
derivation and validation cohorts were also similar to
national breast cancer detection figures [5]. Furthermore,
we used a standard method to identify the predictor vari-
ables and derived a simple to follow rule with moderate
predictive and discriminative ability. The incremental
value of the components of the CPR enables the calcula-
tion of different thresholds of risk. However, the results
need to be interpreted in the context of the study limita-
tions. The data used to inform the analysis was taken from
a single-centre database. Furthermore, our narrow valid-
ation study also utilised patients from the same centre,
thus the model fit may be overestimated. However, we
suspect that these findings can be extrapolated to the
seven other SBUs nationally and most likely reflect the re-
ferral patterns and rates of diagnosis seen in the other
SBUs. We used the clinical findings recorded by the GP at
the time of referral as a proxy for findings of the clinical
examination in the SBU. Therefore the range of symptoms
included in the analysis may not reflect those present in
the SBU. In addition, there is limited information
recorded on side of symptoms, which was not included in
the analysis.
Clinical implications
In Ireland, the introduction of clinical guidelines to
enhance the referral process to SBUs has increased the
referral rate to these units without an increase in the
diagnostic yield. The prioritisation of referrals is not op-
timal either with almost 13% of those with a subsequent
diagnosis of breast cancer initially classified as ‘routine’
or ‘early’ referrals. The proposed clinical prediction rule
discriminates between patients at high risk of breast
cancer from low risk patients and may serve as method
of decreasing the number of unnecessary referrals to
SBUs in women with a low probability of breast cancer.
Our data indicates that the risk of breast cancer is al-
most 2% once a score of 4 is reached and this increased
to over 5% once the score reaches a threshold of ≥6 on
the CPR. However, there is a need for further multi-
centre broad validation studies to explore the optimal
referral threshold. The tradeoff between clinical utility
and patient referral has also been highlighted by other
researchers [8,28]. Selecting a referral threshold would
need to consider a satisfactory tradeoff in cost-effectiveness
between missed cancers and unnecessary investigations.
Consideration also needs to be given to situations wheredoctors suspect a cancer diagnosis even though their
patient may not fit the guidance criteria as these are the
patient group who will have a considerable gain with expe-
dited diagnosis. On the contrary, further research is also
needed to explore alternative strategies to management in
women classified as low risk. For example, a woman aged
25 who presents with nipple changes to her GP has an esti-
mated risk of 5/1000 of breast cancer. Care pathways aside
from referral such as reassurance in primary care and
watchful waiting warrant further consideration.
Conclusions
This study derived and validated a CPR for breast cancer
in symptomatic women attending an Irish national symp-
tomatic breast unit. We found that increasing age, pres-
ence of a lump, nipple discharge and nipple change were
all associated with breast cancer. Validation of the rule
indicates that the probability of breast cancer is higher
with an increasing number of these independent variables.
Further validation of the rule is necessary as well as an
assessment of its impact on referral practice prior to adop-
tion in the clinical setting.
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